FDA-cleared profile

IB Lab LAMA

IB Lab GmbH · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Automatically measures limb-length discrepancy and quantitative knee-alignment parameters on AP full-leg radiographs.

Clinical role
Fully automated software that measures limb-length discrepancy and knee alignment parameters on AP full leg radiographs, compares them with hard-coded norm ranges, and summarizes them in reports the user accepts or rejects in a cleared medical viewer.
Images and patients
X-ray/Radiography · Lower limb/full leg and knee alignment
Key limitation
Keep in mind: Not indicated with ankle arthroplasties or unicompartmental knee arthroplasties; human interpretation remains required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatically measures limb-length discrepancy and quantitative knee-alignment parameters on AP full-leg radiographs.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Lower limb/full leg and knee alignment Input: Unilateral or bilateral AP full-leg radiographs in adults aged 22 years or older.
  • Who uses it?Intended users: Healthcare professionals trained in radiology.
  • What does the software produce?Output: DICOM-viewable length and angle measurements, including MAD, femur, tibia, LLD, HKA, and listed alignment parameters.
  • What is its most important limitation?Key limitation: Not indicated with ankle arthroplasties or unicompartmental knee arthroplasties; human interpretation remains required.

Clinical takeaway. Clinical role: Automatically measures limb-length discrepancy and quantitative knee-alignment parameters on AP full-leg radiographs.

Evidence takeaway. Evidence from the reviewed source record: FDA reported 189 bilateral AP lower-extremity radiographs yielding 325 legs and TKA/THA detection sensitivity 95.05% and specificity 99.80%.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatically measures limb-length discrepancy and quantitative knee-alignment parameters on AP full-leg radiographs.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Fully automated software that measures limb-length discrepancy and knee alignment parameters on AP full leg radiographs, compares them with hard-coded norm ranges, and summarizes them in reports the user accepts or rejects in a cleared medical viewer.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "IB Lab LAMA is a fully-automated radiological image processing software device intended to aid users in the measurement of limb-length discrepancy and quantitative knee alignment parameters on uni- and bilateral AP full leg radiographs" … "The user does not interact directly with IB Lab LAMA except to accept or reject the generated report findings via cleared third party medical viewers.". Read from the exact FDA decision document on 2026-11-14.

Required input
Unilateral or bilateral AP full-leg radiographs in adults aged 22 years or older.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input and population boundary.

Output and clinician action
DICOM-viewable length and angle measurements, including MAD, femur, tibia, LLD, HKA, and listed alignment parameters.
  • Exact FDA submission
  • Checked 2026-09-15

FDA output description.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Healthcare professionals trained in radiology.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet user statement.

Limitations
Not indicated with ankle arthroplasties or unicompartmental knee arthroplasties; human interpretation remains required.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
FDA reported 189 bilateral AP lower-extremity radiographs yielding 325 legs and TKA/THA detection sensitivity 95.05% and specificity 99.80%.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet performance summary.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA reported 189 bilateral AP lower-extremity radiographs yielding 325 legs and TKA/THA detection sensitivity 95.05% and specificity 99.80%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet performance summary.

Reported sensitivity
95.05% (95% CI: 90.29%, 98.96%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
99.80% (95% CI: 99.39%, 100.00%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

IB Lab LAMA regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K223646
  • Samplen=189
  • IndependenceIndependence not established

K223646

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223646. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Unilateral or bilateral AP full-leg radiographs in adults aged 22 years or older.

    Scope: Exact FDA submission. Exact FDA input and population boundary.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K223646: IB Lab LAMA

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · IB Lab LAMA model card (K223646)

  3. AI processing

    Source context, not route validation: The exact FDA package describes IB Lab LAMA as operating in a Linux environment that can be deployed on any operating system supporting the third-party software Docker. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "IB Lab LAMA operates in a Linux environment and can be deployed on any operating system that supports the third-party software Docker.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K223646: IB Lab LAMA

  4. Returned objects

    Source context, not route validation: DICOM-viewable length and angle measurements, including MAD, femur, tibia, LLD, HKA, and listed alignment parameters.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K223646: IB Lab LAMA

  5. Viewer/worklist/report

    Unresolved route: DICOM-viewable length and angle measurements, including MAD, femur, tibia, LLD, HKA, and listed alignment parameters.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K223646: IB Lab LAMA

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes IB Lab LAMA as operating in a Linux environment that can be deployed on any operating system supporting the third-party software Docker. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "IB Lab LAMA operates in a Linux environment and can be deployed on any operating system that supports the third-party software Docker.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for IB Lab LAMA; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223646
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Full-leg radiographs normalized to the controlled X-ray bucket.

Anatomy
Lower limb/full leg and knee alignment
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA anatomy scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-06-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K223646 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K223646: IB Lab LAMA

    U.S. Food and Drug Administration - Published 2023-06-16 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. IB Lab LAMA model card (K223646)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223646

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K223646 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250914

MediAI-BA

Crescom Co., Ltd.

Authorized purpose: View and quantify bone age from 2D posteroanterior left-hand radiographs to aid pediatric radiologists assessing patients aged 2-18 years.

Modality
X-ray/Radiography
Anatomy
Left hand and wrist; skeletal maturity/bone age
Decision
2025-12-18
FDA-cleared K252086

DTX Studio Assist

Nobel Biocare C/O Medicim NV

Authorized purpose: Analyzes two-dimensional bitewing and periapical radiographs of permanent teeth in patients aged 15 and older to identify and localize caries, calculus, periapical radiolucency, root canal filling deficiency, discrepancy at an existing restoration margin, and bone loss; also supports alveolar bone-level measurement and restoration/dental-anatomy segmentation as an adjunct to dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-17
FDA-cleared K250264

SugarBug (1.x)

Bench7, Inc.

Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-07
FDA-cleared K251747

VEA Align; spineEOS

EOS imaging

Authorized purpose: VEA Align is cloud-based software for orthopedic applications in adult and pediatric populations using two-dimensional X-ray images from EOS imaging systems to display interactive landmarks and assess patient-specific global alignment, with angle and length measurements for spinal deformities, degenerative diseases, and lower-limb alignment disorders or deformities. It is suitable for patients aged 7 years and older. spineEOS assists healthcare professionals with preoperative planning of spine surgery using EOS images, associated three-dimensional datasets, measurements, and patient-specific surgical-planning tools.

Modality
X-ray/Radiography
Anatomy
Spine and lower-limb alignment; frontal and lateral EOS images and associated 3D datasets
Decision
2025-08-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history